1356550-62-3

Basic information

• Product Name: 4-(4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoyloxy)butyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylcarbamoyl)benzoate
• Synonyms: 4-(4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoyloxy)butyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylcarbamoyl)benzoate
• CAS NO: 1356550-62-3
• Molecular Weight: 755.995
• Mol File: 1356550-62-3.mol

Chemical Properties

• CAS DataBase Reference: 4-(4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoyloxy)butyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylcarbamoyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoyloxy)butyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylcarbamoyl)benzoate(1356550-62-3)
• EPA Substance Registry System: 4-(4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoyloxy)butyl 4-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-ylcarbamoyl)benzoate(1356550-62-3)

Safety Data

• Hazardous Substances Data: 1356550-62-3(Hazardous Substances Data)

Upstream product

• 1370556-53-8 4-hydroxybutyl 4-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalene-2-carbonyl)benzoate 
• 94497-51-5 Am80 
• 153559-46-7 4-[(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)carbonyl]benzoic acid 

Relevant articles and documents

Synthesis and biological evaluation of novel AM80 derivatives as antileukemic agents

A series of novel AM80 derivatives as antileukemic agents were synthesized and their structures were confirmed by IR, 1H-NMR, and HR-MS spectra. All the target compounds were evaluated for in vitro antiproliferative activities against human leukemic HL-60, NB4, and K562 cell lines. Among these derivatives, compound 4g showed much stronger antiproliferative activities against all the three human leukemic cell lines than the positive control AM80, and compound 4b exhibited more active antiproliferative effects against HL-60 and K562 cells than AM80. Furthermore, the preliminary SAR analysis suggested that AM80 conjugating with HDAC inhibitors with small steric hindrance could give more effective antileukemic agents. These results would be helpful to design more potent antileukemic drugs for the treatment of human leukemia.